ELI LILLY AND COMPANY Treasury Stock, Common, Value
ELI LILLY AND COMPANY (LLY) had Treasury Stock, Common, Value of $62.50 million as of 2025-09-30, per its 10-Q filed 2025-10-30.
Financial Statements › Balance Sheet › Equity › Equity, Including Portion Attributable to Noncontrolling Interest › Equity, Attributable to Parent
us-gaap:TreasuryStockCommonValue · last filed 2025-10-30
- 2025-09-30: Treasury Stock, Common, Value $62.50M.
- 2025-06-30: Treasury Stock, Common, Value $55.40M.
- 2025-03-31: Treasury Stock, Common, Value $49.50M.
- 2024-12-31: Treasury Stock, Common, Value $49.50M.
| Period end | Treasury Stock, Common, Value |
|---|---|
| 2025-09-30 | $62.50M 10-Q · filed 2025-10-30 |
| 2025-06-30 | $55.40M 10-Q · filed 2025-08-07 |
| 2025-03-31 | $49.50M 10-Q · filed 2025-05-01 |
| 2024-12-31 | $49.50M 10-Q · filed 2025-10-30 |
| 2024-09-30 | $32.70M 10-Q · filed 2024-10-30 |
| 2024-06-30 | $32.70M 10-Q · filed 2024-08-08 |
| 2024-03-31 | $32.70M 10-Q · filed 2024-04-30 |
| 2023-12-31 | $44.20M 10-K · filed 2025-02-19 |
| 2023-09-30 | $45.00M 10-Q · filed 2023-11-02 |
| 2023-06-30 | $45.00M 10-Q · filed 2023-08-08 |
| 2023-03-31 | $45.00M 10-Q · filed 2023-04-27 |
| 2022-12-31 | $50.50M 10-K · filed 2024-02-21 |
| 2022-09-30 | $50.50M 10-Q · filed 2022-11-01 |
| 2022-06-30 | $50.50M 10-Q · filed 2022-08-04 |
| 2021-12-31 | $52.70M 10-K · filed 2023-02-22 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Akari Therapeutics Plc (AKTX) | $1,527.991B | -47,921.42 | |
| JOHNSON & JOHNSON (JNJ) | United States | $652.528B | 29.10 |
| AbbVie Inc. (ABBV) | United States | $468.180B | 70.37 |
| Merck & Co., Inc. (MRK) | United States | $365.215B | 99.96 |
| ABBOTT LABORATORIES (ABT) | United States | $176.045B | 28.47 |
| PFIZER INC (PFE) | United States | $162.042B | 31.94 |
| VERTEX PHARMACEUTICALS INC / MA (VRTX) | United States | $132.481B | 28.56 |
| BRISTOL MYERS SQUIBB CO (BMY) | United States | $125.637B | 12.67 |
| REGENERON PHARMACEUTICALS, INC. (REGN) | United States | $74.751B | 21.53 |
| ALNYLAM PHARMACEUTICALS, INC. (ALNY) | United States | $33.420B | 54.94 |